June 12, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 LAGOON trial, conducted by PharmaMar, evaluating Zepzelca® (lurbinectedin) in patients with relapsed (second-line) metastatic small cell lung cancer (SCLC). The trial did not meet its primary endpoint of overall survival (OS) evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators' choice of topotecan or irinotecan. No new safety signals were identifie

June 12, 2026 -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden. Final results from the Phase 3 CLL14 trial in previously untreated chronic lymphocytic leukemia (CLL), which was conducted in collaboration with the German CLL Study Group, will be featured in an oral presentation. "The nine-year results from the landmark Phase 3 CLL14 trial

June 12, 2026 -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). According to the agreement, Simcere Pharmaceutical will fund the exploratory research of this first-in-class novel molecule. Upon successful completion, Simcere wil

The FDA has approved a combination of Merck & Co.'s Keytruda (pembrolizumab) with the company's HIF-2α inhibitor Welireg (belzutifan) as an adjuvant treatment for adults with clear cell renal cell carcinoma (ccRCC) at risk of recurrence after surgery. The approval also applied to Keytruda's subcutaneous formulation, Keytruda Qlex (pembrolizumab/berahyaluronidase alfa-pmph). The decision, which follows a priority review, is based on the Phase III LITESPARK-022 trial, which enrolled 1841 patients

June 11, 2026 -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was supported by one pivotal Phase III clinical study (AK111-301) and three supportive studies. Study results demonstrate gumokimab's rapid and robust efficacy, durable complete skin clear

Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1 with favorable safety pro no observed liver safety concerns 2 With global CIndU prevalence of 29 million 3,4; greater than 50% of patients experience significant disease burden despite treatment with H1-antihistamines; no approved targeted therapies exist 5,6 Rhapsido is under FDA review for CIndU symptomatic dermographism subtype; additional submissions to health au

Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closin

June 9, 2026 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that China's National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for the Phase I ATTRACT study of ATG-20

– ETHY-001 targets the causal pathogenic mechanism underlying both conditions – – Patient-friendly subcutaneous administration with half-life extension for infrequent dosing – – First-in-human clinical trial expected to initiate in the second half of 2026 – – Preclinical data to be presented in an oral presentation at ENDO on June 15, 2026 – – Backed by leading healthcare investors including Atlas Venture, Medicxi Ventures, Avoro Capital, Nandi Life Sciences, and Checkpoint Capital – June 10, 2

Galmed Pharmaceuticals acquired Colospan in a $4.5 million deal as the Israel-based biotech looks to create a gastrointestinal platform targeting a dx sector valued at $6 billion. The deal calls for Colospan shareholders and SAFE (Simple Agreement for Future Equity) holders to get $2.5 million in cash and $2 million in common ordinary shares at the close, which is expected to be completed by the end of the second quarter this year, the company said in a June 8 press release. The sale has been